Long-Term Treatment of Girls with Ornithine Transcarbamylase Deficiency

Abstract

Girls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline.